Alnylam Pharmaceuticals (ALNY) Revenue Growth (5y) (2014 - 2026)
Alnylam Pharmaceuticals (ALNY) Revenue Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.73% |
| Dec 31, 2025 | 46.32% |
| Sep 30, 2025 | 58.25% |
| Jun 30, 2025 | 49.40% |
| Mar 31, 2025 | 42.97% |
| Dec 31, 2024 | 52.60% |
| Sep 30, 2024 | 48.20% |
| Jun 30, 2024 | 71.32% |
| Mar 31, 2024 | 71.53% |
| Dec 31, 2023 | 83.68% |
| Sep 30, 2023 | 225.03% |
| Jun 30, 2023 | 60.52% |
| Mar 31, 2023 | 70.90% |
| Dec 31, 2022 | 54.61% |
| Sep 30, 2022 | 72.92% |
| Jun 30, 2022 | 69.79% |
| Mar 31, 2022 | 62.26% |
| Dec 31, 2021 | 71.45% |
| Sep 30, 2021 | 68.90% |
| Jun 30, 2021 | 90.86% |